Terns Pharmaceuticals, Inc. (TERN) EBT (2020 - 2023)
Terns Pharmaceuticals (TERN) has disclosed EBT for 4 consecutive years, with $69.0 million as the latest value for Q4 2023.
- For the quarter ending Q4 2023, EBT rose 545.35% year-over-year to $69.0 million, compared with a TTM value of $46000.0 through Dec 2023, up 100.08%, and an annual FY2024 reading of -$88.6 million, down 192693.48% over the prior year.
- EBT was $69.0 million for Q4 2023 at Terns Pharmaceuticals, up from -$29.7 million in the prior quarter.
- Across five years, EBT topped out at $69.0 million in Q4 2023 and bottomed at -$29.7 million in Q3 2023.
- Average EBT over 4 years is -$9.4 million, with a median of -$13.5 million recorded in 2021.
- Peak annual rise in EBT hit 545.35% in 2023, while the deepest fall reached 76.77% in 2023.
- Year by year, EBT stood at -$10.4 million in 2020, then crashed by 33.64% to -$13.9 million in 2021, then fell by 11.57% to -$15.5 million in 2022, then soared by 545.35% to $69.0 million in 2023.
- Business Quant data shows EBT for TERN at $69.0 million in Q4 2023, -$29.7 million in Q3 2023, and -$17.8 million in Q2 2023.